



BIOSHARES SUMMIT 2022

Riccardo Canevari
CEO, Radiopharm Theranostics Ltd



DISCLAIMER

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in RadioPharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.


Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change.


WHAT IS THE NEW FRONTIER IN ONCOLOGY? AND THE NEXT \$40B PLATFORM?

WORLDWIDE ONCOLOGY MARKET in 2025 = **~290B\$**; CAGR 5y (2020-2025) = **13%**
CHEMO and TARGETED Therapies = **~190 B\$**; CAGR 5y (2020-2025) = **9%**



RADIOPHARMACEUTICAL THERAPIES HAS THE POTENTIAL TO TRANSFORM THE TREATMENT PARADIGM

WORLDWIDE ONCOLOGY MARKET in 2025 = **~290B\$**; CAGR 5y (2020-2025) = **13%**
CHEMO and TARGETED Therapies = **~190 B\$**; CAGR 5y (2020-2025) = **9%**



EXCITING SCIENTIFIC EVIDENCE IS CHANGING THE TREATMENT PARADIGM

 **Memorial Sloan Kettering Cancer Center**
Sloan Kettering Institute Locations Doctors

Adult Patients ▾ Child & Teen Patients ▾ Refer a Patient Healthcare Professionals ▾ Re

News & Information / In the News

FDA Approves Promising Therapy for Advanced Prostate Cancer: Targets a Protein Called PSMA

 **JNM**
The Journal of Nuclear Medicine

search Advanced Search 

Home Content ▾ Subscriptions ▾ Authors ▾ Info ▾ About ▾ More ▾    

Research Article | The State of the Art

Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer

 **Oncology**

The PSMA-Targeting Era: A Game-Changer for Men with Prostate Cancer Worldwide

 **NATIONAL CANCER INSTITUTE**

1-800-4-CANCER

ABOUT CANCER CANCER TYPES RESEARCH GRANTS & TRAINING **NEWS & EVENTS** ABOUT N

Home > News & Events > Cancer Currents Blog

Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age

 **Department of Radiology**
University of Wisconsin School of Medicine and Public Health

Home People ▾ Education ▾ Sections ▾ Diversity & Inclusion ▾ Research ▾ Referring Clinicians News Contact

HOME / SECTIONS / NUCLEAR MEDICINE AND PET IMAGING / RADIOLOGY DEPARTMENT PAVES WAY FOR REVOLUTIONARY NEUROENDOCRINE TUMOR TREATMENT

Radiology Department Paves Way for Revolutionary Neuroendocrine Tumor Treatment

Posted on July 2019

CANCER CARE | July 29, 2021

Clinic transforms cancer treatment by combining diagnosis and therapy – or theranostics

INCREASING NUMBER OF BOLT ON ACQUISITIONS IN RADIOPHARMACEUTICALS



Our Company ▾ Our Focus ▾ Our

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)



HOME SERVICES NEWS EDUCATION ABOUT US

Search

Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer

- Broadens company's oncology platform of Targeted Alpha Therapies (TATs)
- Acquisition includes actinium-225 labeled differentiated prostate-specific membrane antigen (PSMA) small molecule being studied as an investigational compound in prostate cancer

June 03, 2021 08:00 AM Eastern Daylight Time

BRIEF

AstraZeneca partners with Fusion to test radiopharmaceuticals in cancer

Published Nov. 2, 2020

March 18, 2021 09:57 AM EDT Updated 05:41 PM | Financing, Deals



Top biotech investor Peter Kolchinsky tees up a new SPAC — 3 days after a \$300M raise for radiopharmaceuticals play

Evaluate Vantage March 31, 2021

Deals

Radiotherapeutics remain in the deal-making frame



Jacob Plieth



A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.

FEATURE | RADIATION ONCOLOGY | MAY 04, 2021 | BY VINAY SHIVAPRASAD

The Rise of Therapeutic Radiopharmaceuticals

The emergence of therapeutic radiopharmaceuticals and its adoption in cancer care provide one more weapon in combating cancer

GLOBAL BANKING &
Finance
review

TOP STORIES INTERVIEWS BUSINESS FINANCE BANKING TECHNOLOGY INVESTING TRADING

RESEARCH REPORTS

Strategic Mergers and Acquisitions to Surge the Demand for Radiopharmaceuticals Market

ONLY PROSTATE AND NET BENEFIT FROM RADIOPHARMACEUTICALS, ONLY THREE BIG PHARMA ARE ACTIVE IN THE SECTOR



		2019 Rx Sales*	2019 R&D Spend*
★	1 Roche BASEL, SWITZERLAND (ROCHE.COM)	\$48.247	\$10.293
★	2 Novartis BASEL, SWITZERLAND (NOVARTIS.COM)	\$46.085	\$8.386
	3 Pfizer NEW YORK, NEW YORK (PFIZER.COM)	\$43.662	\$7.988
	4 Merck & Co. KENILWORTH, NEW JERSEY (MERCK.COM)	\$40.903	\$8.730
	5 Bristol Myers Squibb** NEW YORK, NEW YORK (BMS.COM)	\$40.689	\$9.381
	6 Johnson & Johnson NEW BRUNSWICK, NEW JERSEY (JNJ.COM)	\$40.083	\$8.834
	7 Sanofi PARIS, FRANCE (SANOFI.COM)	\$34.924	\$6.071
	8 AbbVie NORTH CHICAGO, ILLINOIS (ABBVIE.COM)	\$32.351	\$4.989
	9 GlaxoSmithKline BRENTFORD, ENGLAND (GSK.COM)	\$31.288	\$5.541
	10 Takeda OSAKA, JAPAN (TAKEDA.COM)	\$29.247	\$4.432
★	11 AstraZeneca LONDON, ENGLAND (ASTRAZENECA.COM)	\$23.207	\$5.320
	12 Amgen THOUSAND OAKS, CALIFORNIA (AMGEN.COM)	\$22.204	\$4.027
	13 Gilead Sciences FOSTER CITY, CALIFORNIA (GILEAD.COM)	\$21.703	\$4.059
	14 Eli Lilly INDIANAPOLIS, INDIANA (LILLY.COM)	\$20.085	\$5.595
★	15 Bayer LEVERKUSEN, GERMANY (BAYER.COM)	\$18.610	\$3.081
	16 Novo Nordisk BAGSVERD, DENMARK (NOVONORDISK.COM)	\$18.296	\$2.132
	17 Boehringer Ingelheim INGELHEIM, GERMANY (BOEHRINGER-INGELHEIM.COM)	\$15.629	\$3.038
	18 Allergan IRVINE, CALIFORNIA (ALLERGAN.COM)	\$15.153	\$1.709
	19 Astellas Pharma TOKYO, JAPAN (ASTELLAS.COM)	\$11.444	\$1.976
	20 Biogen CAMBRIDGE, MASSACHUSETTS (BIOGEN.COM)	\$11.380	\$2.281

Source: EvaluatePharma® May 2020, Evaluate Ltd, www.evaluate.com

CDC: Estimated (2015) cancer cases and projected additional cases (2050) by cancer site, United States

THE ROLE OF RADIOPHARM THERANOSTICS



Founded:	February 2021
Where:	Australia
1st Capital Raise:	\$20m Jul 2021
2nd Capital Raise:	\$50m IPO Nov 2021
ASX Ticker:	RAD

AMBITION:

become the recognized Leader in fighting cancer,
through innovative radiopharmaceutical therapies,
in areas of high unmet medical needs

EXECUTIVE LEADERSHIP TEAM



**RICCARDO
CANEVARI**

MANAGING DIRECTOR / CEO

Riccardo was most recently **Chief Commercial Officer of Novartis company Advanced Accelerator Applications**, one of the leading radiopharmaceutical companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia. He was lead for **Lutathera** in-market growth strategy and lead on the prelaunch plan for **Lu-PSMA 617** in metastatic prostate cancer. Prior to this he was **Senior VP and Global Head, Breast Cancer** Franchise for Novartis Oncology from 2017, overseeing the launch of major breast cancer products including **KISQALI** and **PIQRAY**. He has held various management roles with Novartis Pharma and Johnson&Johnson.



**PROF DAVID
MOZLEY**

CHIEF MEDICAL OFFICER

David was most recently at **Cornell University** where he was **Prof of Nuclear Medicine**, Medical Director of the imaging research centre, and Director of the Multi-Center Clinical Translational Science Center. He was an active member of the ethics board and a past chair of the Cornell ethics board for cancer research. He has participated in over **60 clinical trials** at **Eli Lilly** and over **100 trials at Merck** in novel radio-pharmaceutical or drug development. He was the principal investigator of 11 first-in-human studies of novel radiopharmaceuticals at the University of Pennsylvania, and the sponsor of nine investigational radiopharmaceuticals at Cornell. He has **co-authored more than 100 peer-reviewed publications**.



**DR THOM
TULIP**

CHIEF TECHNICAL OFFICER

Thom has spent more than **25 years in the development and commercialization of radiopharmaceuticals** and imaging agents. He has served in senior leadership roles at **Navidea BioPharmaceuticals Inc**, **Alseres Pharmaceuticals**, **Lantheus Medical Imaging (LMI)**, **Bristol Myers Squibb (BMS)**, and **DuPont**. He was a Board Member of the Academy of Molecular Imaging and Chairperson of its Institute for Molecular Technologies.



**PAUL
HOPPER**


EXECUTIVE CHAIRMAN

Paul is the **Founder of Radiopharm Theranostics**. **25 years experience in biotech, healthcare and life sciences** focused on **start-up and rapid growth companies**. Previous and current Boards include **Imugene**, **Chimeric Therapeutics**, **Viralytics** (sold to Merck in 2018 for \$500m), **Prescient**, **Polynoma**, **Arovella Pharmaceuticals**.




FIVE DISTINCT & WELL DIFFERENTIATED PLATFORMS

ONE OF THE DEEPEST PIPELINE OF RADIOPHARMACEUTICAL THERAPIES



SCIENTIFIC ADVISORY BOARD

Pivalate



PROF ERIC ABOAGYE

AVβ6 Integrin



DR JOHANNES NOTNI

Nano-mAbs



DR HONG HOÏ TING



PROF SARA HURVITZ

PSA-mAb

DUNP 19



DR DAVID ULMERT

Eric Aboagye is a **Professor of Cancer Pharmacology** and Molecular Imaging at **Imperial College London**. He is a Fellow of the Academy of Medical Sciences and was awarded the British Institute of Radiology Sir Mackenzie Davidson Medal in 2009. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application. He has acted as an advisor to GE-Healthcare, GSK, Roche and Novartis.



Dr Notni is an acknowledged authority in the field of integrins and nuclear medicine. Until recently he was **Professor at the Technical University of Munich** where his research interests included radiometal complexes for nuclear imaging and therapy, MRI contrast agents, as well as preclinical evaluation and clinical translation of innovative radiopharmaceuticals in particular integrins. He received several awards, "Radiopharmaceutical Council Young Investigator Award, 1st Prize" of the Society of Nuclear Medicine (2011) and the Innovation Prize in Medicinal and Pharmaceutical Chemistry from the Gesellschaft Deutscher Chemiker (GdCh) and Deutsche Pharmazeutische Gesellschaft (DPhG) (2013). In 2016, he received the EANM Springer Prize for the most cited paper in EJNMMI Research, and in 2017, the Georg von Hevesy Prize from the Deutsche Gesellschaft für Nuklearmedizin (DGN).



University Medicine Essen
University Hospital

Dr Hong obtained his doctorate from the **University of Oxford** and has built an internationally recognised career as a radiopharmaceutical and nuclear medicine expert. He has worked in both industry and academia including Oxford, Westinghouse, Johnson and Johnson, GE Healthcare and C.A.S. Shanghai National Technology Centre. He is currently head consultant in nuclear medicine for CGN Nuclear Technology and a strategic consultant to ITM, a major German nuclear medicine isotopes supplier. He is the founder of NanoMab Technology Ltd from which Radiopharm licensed HER-2, TROP-2, PD-L1 and PTK7 targeting technologies.



Sara A Hurvitz, MD, is **Professor of Medicine at the University of California, Los Angeles (UCLA)**; co-director of the Santa Monica-UCLA Outpatient Oncology Practice; **Medical Director** of the Clinical Research Unit of the Jonsson Comprehensive **Cancer Center at UCLA; and Director of Breast Oncology**. Dr. Hurvitz earned her MD from the University of Southern California. Dr. Hurvitz received board-certification in internal medicine, hematology, and medical oncology. Dr. Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015. She has an active clinical practice specializing in the treatment of women with breast cancer. She is involved in designing, implementing and leading multiple national and international clinical trials testing new targeted therapies and also leads the preclinical evaluation of novel breast cancer targets in the Translation Oncology Research Laboratory at UCLA.



Dr Ulmert obtained his **medical degree at Lund University in Sweden**. Formerly of **Memorial Sloan Kettering** and now **UCLA**. He has served as a Senior Research Scientist in the Medical Pharmacology Program and as the Technical Director for the Ludwig Center for Cancer Immunotherapy since 2014. Dr. Ulmert's clinical research is focused on the study of risk factors and biomarkers related to clinically diagnosed prostate cancer and definitive end-points in non-screened cohorts. The overarching goal is to apply these specific tissue targeting vehicles for multimodal molecular imaging strategies, as well as for carriers of therapeutic agents.



BUILD A LEADERSHIP POSITION TARGETING KEY PATHWAYS WITH MULTIPLE INNOVATIVE MOLECULES

	Cancer type	New Cases	RAD Pipeline	Target / Moa
1	Breast	280.000	✓ ✓	HER2 / TROP2
2	Prostate	248.000	✓	KLK3
3	Lung	235.000	✓	PDL1
4	Colorectal	149.000		
5	Melanoma	106.000		
6	Bladder	83.000		
7	Kidney	76.000		
8	Uterine	66.000	✓	PTK7
9	Head & Neck	66.000	✓	INTEGRIN $\alpha v \beta 6$
10	Pancreatic	60.000	✓	INTEGRIN $\alpha v \beta 6$
	Glioblastoma	18.000	✓	FATTY ACID
	Osteosarcoma	1.000	✓	LRRC15

SEER database: US incidence

SCIENTIFIC WINNING PROPOSITION: COMBINING THE RIGHT MOLECULE WITH THE RIGHT ISOTOPE IN THE RIGHT DISEASE AREA

* Deal signed


** Deal to be signed in the next 90 days

Unique molecules

1	HER2 nanobody	2	PDL1 nanobody
3	PTK7 nanobody	4	TROP2 nanobody
5	INTEGRIN $\alpha v \beta 6$	6	PSA-Mab
7	Pivalate	8	DUNP-19

Therapeutic Isotopes


1	Ac225*	α emitter
2	Re188*	β emitter
3	Lu177**	β emitter
4	Tb161**	β emitter
5	I131**	β emitter




9 solid tumors areas targeted

1	HER2 Breast	4	TNBC Breast	7	Glioblastoma
2	Lung	5	Pancreatic	8	Osteosarcoma
3	Ovarian	6	Prostate	9	Head & Neck

NEXT 18 MONTH - DEVELOPMENT PLAN





NEXT 18 MONTH - DEVELOPMENT PLAN





OUR MOST RECENT ACQUISITION

DUNP19: Humanized mAb targeting LRRC15 expression



Unique MoA and very fast internalization



LRRC15 IS HIGHLY PRESENT IN MULTIPLE TUMOR TYPES, WITH VERY LIMITED EXPRESSION IN HEALTHY TISSUES



Potential superior profile vs FAPi




1. Adrenocortical carcinoma
2. Bladder Urothelial Carcinoma
3. Breast invasive carcinoma
4. Cervical/endocervical carcinoma
5. Cholangio carcinoma
6. Colon adenocarcinoma
7. Lymphoid neoplasm/B-cell lymphoma
8. Esophageal carcinoma
9. Glioblastoma multiforme
10. Head and neck squamous cell carcinoma
11. Renal chromophobe
12. Renal clear cell carcinoma
13. Renal papillary cell carcinoma
14. Acute Myeloid Leukemia
15. Lower grade glioma
16. Hepatocellular carcinoma
17. Lung adenocarcinoma
18. Lung Squamous cell carcinoma
19. Ovarian serous cystadenocarcinoma
20. Pancreatic adenocarcinoma
21. Pheochromocytoma
22. Prostate adenocarcinoma
23. Rectum adenocarcinoma
24. Sarcoma
25. Cutaneous melanoma
26. Stomach adenocarcinoma
27. Testicular Germ cell tumors
28. Thyroid carcinoma
29. Thymoma
30. Endometrial carcinoma
31. Uterine carcinosarcoma

IN A FAST-GROWING MARKET, WITH ONE OF THE DEEPEST PIPELINES




Radiopharmaceutical Therapies has the potential to be the **new frontier** in ~290B\$ **Oncology market**




Radiopharmaceutical Therapies can play a **significant role in areas of high unmet need**



Radiopharmaceuticals experiencing a high level of **investor interest and M&A activity**



one **of the deepest pipeline** in the sector



Over 150 patients treated to date across **several clinical trials in humans**



We maintain **opportunistic Business Development** strategy



Ambition to **improve outcomes for patients** living with **Oncological diseases**

CONTACT US

Riccardo Canevari

CEO & MANAGING DIRECTOR
Radiopharm Theranostics Limited

T +1 862 309 0293

E rc@radiopharmtheranostic.com

W www.radiopharmtheranostics.com

Paul Hopper

Executive Chairman
Radiopharm Theranostics Limited

T +61 406 671 515

E paulhopper@lifescienceportfolio.com

W www.radiopharmtheranostics.com